盐酸氯雷他定 | 444995-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并环庚烷吡啶
• 中文名称: 盐酸氯雷他定
• 英文名称: Loratadine specified impurity E
• 英文别名: ethyl 4-(13-chloro-4-azatricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene)piperidine-1-carboxylate;hydrochloride
• CAS: 444995-23-7
• 化学式: C22H24Cl2N2O2
• 分子量: 419.3
• InChiKey: DUWMKTXPAFUTGI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.31
• 重原子数：
  28
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] METHOD OF MAKING ORAL DOSAGE FORMS<br/>[FR] PROCÉDÉ DE FABRICATION DE FORMES PHARMACEUTIQUES ORALES
  申请人：UNIV HEIDELBERG

  公开号：WO2020065054A1

  公开（公告）日：2020-04-02

  The present invention relates to a method of making an oral dosage form comprising the steps of reacting at least one cell penetrating peptide (CPP), purifying CPP-lipid conjugates, processing a lipid batch to obtain CPP-modified liposomes and incorporating a liposome lyophilisate into an oral dosage form. The present invention further relates to oral dosage forms and oral dosage forms for use in a therapeutic method.

  本发明涉及一种制备口服剂型的方法，包括以下步骤：反应至少一种细胞穿透肽（CPP），纯化CPP-脂质共轭物，处理脂质批次以获得CPP修饰的脂质体，并将脂质体冻干粉末合并到口服剂型中。本发明还涉及用于治疗方法的口服剂型和口服剂型。
• PROCESS FOR PREPARATION OF OVER-THE-COUNTER GELATIN OR PECTIN-BASED DRUG DELIVERY
  申请人：Lowther Stuart A.

  公开号：US20130005740A1

  公开（公告）日：2013-01-03

  Disclosed herein is a process producing a therapeutic comestible gummie product, the process comprises providing a sugar and/or sugar alcohol, water and heating to at least 80° C. to produce a first mixture. A gelling agent and water is also provided and heat to at least 80° C. to produce a second mixture. Combining the first and second mixtures to produce a slurry. The slurry is heated to at least 112° C. to produce a gummie base. The gummie base is cooled to an optimal temperature of below 90° C. for the addition of an active drug and the active drug is substantially uniformly mixed with the gummie base. In some embodiments the active is drug is mixed with an ingestible oil and added to the cooling slurry. The gummie base and active drug mixture is then poured into molding trays and allowed to cure. Also disclosed herein by way the process of the present disclosure is therapeutic comestible gummie product. Furthermore, the present disclosure comprises a therapeutic comestible gummie product comprising ibuprofen and/or other active drug(s).

  本文揭示了一种制造治疗性口服软糖产品的过程，该过程包括提供糖和/或糖醇、水并加热至至少80℃以制成第一混合物。还提供了一种凝胶剂和水，并加热至至少80℃以制成第二混合物。将第一混合物和第二混合物混合以产生浆糊。将浆糊加热至至少112℃以产生软糖基础。将软糖基础冷却至最佳温度低于90℃，以添加活性药物，并将活性药物与软糖基础基本均匀混合。在某些实施例中，活性药物与可食用油混合，并加入冷却的浆糊中。然后，将软糖基础和活性药物混合物倒入成型托盘中并进行固化。此外，本文还揭示了一种治疗性口服软糖产品的制备方法。此外，本文还包括一种含有布洛芬和/或其他活性药物的治疗性口服软糖产品。
• Gel enthaltend Cetirizin und Loratadin zur topischen Anwendung
  申请人：Oramon Arzneimittel GmbH

  公开号：EP1327463A1

  公开（公告）日：2003-07-16

  Die vorliegende Erfindung betrifft eine Arzneimittelzubereitung, enthaltend die nicht sedierenden H1-Antihistaminika Cetirizin, Loratadin, Mischungen oder pharmazeutisch annehmbare Salze derselben, für die topische Anwendung in Form eines Gels.

  本发明涉及一种药物制剂，含有非镇静型 H1-抗组胺药西替利嗪、氯雷他定、其混合物或药学上可接受的盐，以凝胶形式局部使用。
• LIPOSOMES CONTAINING CELL PENETRATING PEPTIDES AND TETRAETHERLIPIDS FOR THE ORAL DELIVERY OF MACROMOLECULES
  申请人：Universität Heidelberg

  公开号：EP3158992A1

  公开（公告）日：2017-04-26

  The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double Iayer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.

  本发明涉及脂质体组合物，包括由四醚脂质（TELs）和细胞穿透肽（CPPs）组成的脂质体，其中所述CPPs附着在作为脂质体脂质双层的一部分的化合物上。本发明还涉及其在口服给药和/或诊断制剂方面的用途。
• COMPOSITION FOR EXTERNAL APPLICATION
  申请人：Rohto Pharmaceutical Co., Ltd.

  公开号：EP3210613A1

  公开（公告）日：2017-08-30

  An object of the present invention is to provide an external use composition having a novel composition that has a superior effect promoting collagen production and is able to suppress, prevent or improve wrinkles and sagging of the skin with aging. The present invention relates to an external use composition for anti-aging, comprising (A) a lipopeptide represented by the following formula (1), or a pharmaceutically acceptable salt thereof: (wherein, R1 represents a saturated aliphatic group, or aliphatic group having a single unsaturated bond, having 9 to 19 carbon atoms, and m represents 0 or 1).

  本发明的目的是提供一种外用组合物，该组合物具有新颖的成分，具有促进胶原蛋白生成的卓越效果，能够抑制、预防或改善随着衰老而出现的皱纹和皮肤松弛。 本发明涉及一种用于抗衰老的外用组合物，其中包括 (A) 下式（1）代表的脂肽或其药学上可接受的盐： (其中，R1 代表具有 9 至 19 个碳原子的饱和脂肪族基团或具有单个不饱和键的脂肪族基团，m 代表 0 或 1）。